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Purpose: The purpose of this study was to examine the associations between ultrasonography (US) 
quality and clinical outcomes in patients undergoing surveillance for hepatocellular carcinoma.
Methods: Between 2008 and 2013, 155 patients were diagnosed with liver cancer during 
regular surveillance by positive US results (US group, n=82) or by computed tomography (CT) 
or magnetic resonance image (MRI) scanning as alternative modalities (CT/MRI group, n=73). 
The quality of the echogenic window, macronodularity of the liver parenchyma, and occurrence 
of surveillance failure (initial tumor diagnosis beyond the Milan criteria or at Barcelona Clinic 
Liver Cancer stage B or C) were evaluated. Overall survival was compared according to whether 
surveillance failure occurred.
Results: The patients in the CT/MRI group with negative US results had a higher proportion of 
parenchymal macronodularity on US than those in the US group (79.5% vs. 63.4%, P=0.028). 
Surveillance failure tended to be more common in the US group than in the CT/MRI group (40.2% 
vs. 26.0% by the BCLC staging system [P=0.061]). In the US group, surveillance failure occurred 
more frequently when the echogenic window was inadequate (50.0% vs. 19.4% by the Milan 
criteria [P=0.046]). Significantly poorer 5-year overall survival was associated with surveillance 
failure (P≤0.001).
Conclusion: Parenchymal macronodularity hindered the detection of early-stage tumors during 
US surveillance. Using an alternative imaging modality may help prevent surveillance failure in 
patients with macronodular parenchyma on US. Supplemental surveillance strategies than US 
may also be necessary when the echogenic window is inadequate.
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Introduction
Liver cancer is the fourth leading cause of cancer-related death 
worldwide [1]. Surveillance is recommended for patients at high 
risk of developing hepatocellular carcinoma (HCC) to detect the 
tumor at an early stage and render curative treatment [2]. A general 
recommendation for HCC surveillance is biannual ultrasonography 
(US) with or without serum α-fetoprotein (AFP) testing [2,3]. 
Evidence suggests that surveillance for HCC is associated with 
significant improvements in patient survival [4,5].
However, concerns have been raised that the proportion of early-
stage HCC diagnoses during surveillance is not sufficiently high. 
It has been reported that surveillance enables early-stage tumor 
diagnosis in only two-thirds of patients with cirrhosis [6,7]. In other 
words, surveillance failure, defined as late-stage HCC diagnosis 
despite surveillance, occurs in about one-third of patients under 
surveillance. Surveillance failure can occur due to a lack of regular 
periodic screening, the absence of a prompt diagnostic evaluation 
after obtaining a positive surveillance result, or even despite 
conforming to the recommended screening and diagnostic protocols 
[8].
Surveillance failure is meaningfully influenced by the performance 
of the imaging modality used for surveillance. It has been reported 
that US has suboptimal sensitivity for detecting early-stage HCC, 
which is likely a major cause of surveillance failure [9]. Therefore, 
it is crucial to elucidate the factors that contribute to the limited 
sensitivity of US. Although various clinical factors have been 
examined to identify possible associations with surveillance 
failure [6,10-12], few researchers have evaluated factors related 
to the US modality itself that may affect tumor detectability 
during surveillance [13]. At our institution, in addition to findings 
concerning nodules suspected to be malignant, the adequacy of the 
echogenic window and the status of the liver parenchyma are also 
routinely recorded in the surveillance US reporting form, as these 
factors may affect the detectability of small nodules. Our hypothesis 
was that the detectability of small nodules during surveillance US 
may be hindered by the inadequacy of the echogenic window and 
parenchymal macronodularity. Therefore, we aimed to investigate 
the associations between US quality, as assessed by adequacy of 
the echogenic window and the status of the liver parenchyma, and 
clinical outcomes in patients undergoing surveillance for HCC.
Materials and Methods
Patients
Approval from the local Institutional Review Board was obtained 
and the requirement for patient consent was waived due to the 
retrospective nature of this study. Our search of patients' electronic 
medical records revealed 2,166 patients at risk for HCC (due to 
hepatitis B virus surface antigen positivity, hepatitis C antibody 
positivity, or liver cirrhosis of any etiology) who underwent 
abdominal US for HCC surveillance from January 2008 to December 
2013 at a single tertiary medical center. We excluded 1,783 patients 
who had been previously treated for liver cancer (n=465), who 
received no tumor diagnosis (n=1,220), or who underwent only 
a single screening US examination (n=98). Of the remaining 383 
treatment-naïve at-risk patients who were diagnosed with liver 
cancer during surveillance, we excluded 206 patients who were 
diagnosed with liver cancer based on the initial surveillance US 
(n=91) or who did not have an interval of 4 to 8 months between 
the final screening round and the prior screening round (failure 
of screening, n=115) [10]. We also excluded 22 patients who did 
not undergo diagnostic computed tomography (CT) or magnetic 
resonance imaging (MRI) within 6 months after obtaining positive 
surveillance US (failure of follow-up, n=6), who received a 
histopathologic diagnosis of a non-HCC malignancy (n=11), or who 
were in Child-Pugh class C (n=5). Our final study cohort consisted 
of the remaining 155 patients (Fig. 1). The patients were either 
diagnosed with liver cancer by positive US surveillance results (US 
group, n=82) or by CT or MRI performed as an alternative modality 
after obtaining negative US surveillance results (CT/MRI group, 
n=73).
HCC Surveillance and Diagnosis
At our institution, surveillance for HCC is performed for at-
risk patients by biannual abdominal US and serum AFP testing. 
Surveillance US is performed by hepatology residents or fellows 
with 1 to 4 years of experience in abdominal US. Our abdominal 
US reporting form includes (1) quality of the echogenic window 
(acceptable, poor, or unacceptable); (2) type of liver cirrhosis 
(macronodular, micronodular, or no gross evidence of cirrhosis); (3) 
degree of fatty liver (mild, moderate, severe, or no gross evidence 
of fatty liver); (4) number, size, and location of any space-occupying 
lesion; (5) presence or absence of splenomegaly; and (6) presence 
or absence of vascular thrombosis. The assessment of the echogenic 
window is based on the estimated proportion of scanned area to 
the entire liver; if some portions or only small portions of the liver 
are visualized on US, the echogenic window quality is rated as poor 
or unacceptable, respectively. Cirrhosis is classified as macronodular 
or micronodular depending on the presence of numerous cirrhosis-
associated nodules ≥3 mm or <3 mm, respectively.
If any space-occupying lesion measuring >1 cm was newly 
detected by US, or the serum AFP level was above 20 ng/mL, the 
surveillance test was considered positive, and the patient underwent 
Effect of US quality on HCC surveillance
e-ultrasonography.org Ultrasonography 38(4), October 2019 313
dynamic contrast-enhanced CT or MRI. In some cases, CT or MRI 
was performed to evaluate patients’ symptoms or as an alternative 
tool for surveillance under clinical suspicion of liver cancer. The 
diagnosis of HCC was based on the radiological findings of CT or 
MRI or on histological evidence, according to the guidelines of the 
American Association for the Study of Liver Disease [2].
Data Collection
A board-certified radiologist with 8 years of experience in abdominal 
imaging (C.A.) reviewed the electronic medical records, including the 
prospectively written radiology reports. To test our hypothesis, the 
quality of the echogenic window was dichotomized into adequate 
(acceptable) or inadequate (poor or unacceptable) based on the 
US reports. In addition, a board-certified radiologist with 4 years of 
experience in abdominal imaging (Y.Y.K.) retrospectively reviewed 
the sonograms, blinded to clinical information, in order to classify 
the patients as with or without parenchymal macronodularity. 
The presence of numerous cirrhosis-associated nodules ≥3 mm 
that made the hepatic echotexture markedly heterogeneous was 
considered indicative of macronodular liver cirrhosis. For patients 
in the US group, the US report and images from the prior screening 
round were reviewed; for those in the CT/MRI group, the US report 
and images from the final screening round were reviewed. 
The clinical information that was examined included age, sex, 
body mass index (BMI), etiology of liver disease, Child-Pugh class, 
serum AFP level, serologic laboratory data, the presence or absence 
of diabetes mellitus (DM), final pathological diagnosis, and survival 
information. Based on radiology reports and clinical data, tumor 
stage at the time of the initial diagnosis was determined according 
to the Milan criteria or the Barcelona Clinic Liver Cancer (BCLC) 
staging system. Surveillance failure was defined as an initial tumor 
diagnosis beyond the Milan criteria or at BCLC stage B or C despite 
regular surveillance.
Statistical Analysis
The patient characteristics and tumor stage were compared between 
the US group and the CT/MRI group using the chi-square test for 
categorical variables and the Student t test for continuous variables. 
The chi-square test or the Fisher exact test was used to compare 
tumor stage according to the quality of the echogenic window and 
the presence or absence of parenchymal macronodularity in the 
US group; this analysis was not performed in the CT/MRI group, 
as tumor stage can be affected by the intervention of CT and 
MRI scanning and by the quality of surveillance US. Inter-observer 
agreement in the evaluation of echogenic window quality between 
the final screening round and the prior screening round was 
compared using kappa statistics [14]. We used logistic regression to 
identify clinical factors associated with adequacy of the echogenic 
window or the presence of parenchymal macronodularity on 
surveillance US. Continuous variables were dichotomized according 
Fig. 1. Flowchart of the study participants. HCC, hepatocellular carcinoma; US, ultrasonography; CT, computed tomography; MRI, magnetic 
resonance imaging.
Patients at risk of developing HCC who underwent surveillance US
between 2008 and 2013 (n=2,166) Excluded (n=1,783)
- Previously treated for liver cancer (n=465)
- No tumor diagnosis (n=1,220)
- Surveillance only once (n=98)
Excluded (n=206)
- Tumor diagnosis at initial US (n=91)
- Screening failure (n=115)
Excluded (n=22)
- Follow-up failure (n=6)
- Histopathologic diagnosis of non-HCC
  malignancy (n=11)
- Child-Pugh class C (n=5)
Patients diagnosed with liver cancer (n=383)
Patients diagnosed with liver cancer during regular surveillance (n=177)
Final study subjects (n=155)
- US group: Tumor diagnosis by US (n=82)
- CT/MRI group: Tumor diagnosis by alternative CT or MRI (n=73)
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C virus infection (11.0%). Most patients (93.5%) were in Child-Pugh 
class A. The patients in the US group and those in the CT/MRI group 
did not differ significantly in terms of age, sex, BMI, etiology of liver 
disease, and Child-Pugh classification. The proportion of patients 
with DM or an AFP elevation ≥20 ng/mL tended to be higher in the 
CT/MRI group (50.7% vs. 35.4% for DM [P=0.054] and 50.7% vs. 
36.6% for AFP elevation [P=0.077]), but this trend did not reach 
statistical significances.
With regard to the quality of surveillance US, 16.8% (26 of 155) 
and 71.0% (110 of 155) of patients had an inadequate echogenic 
window and parenchymal macronodularity, respectively. Patients 
in the CT/MRI group had higher proportions of an inadequate 
echogenic window (Fig. 2) and parenchymal macronodularity 
(Fig. 3) than those in the US group (19.2% vs. 14.6% for an 
inadequate echogenic window [P=0.450] and 79.5% vs. 63.4% 
for parenchymal macronodularity [P=0.028]). The inter-observer 
agreement for adequacy of the echogenic window was moderate 
(κ=0.44).
In the entire study population, tumors were initially detected 
beyond the Milan criteria in 31 patients (20.0%) and at BCLC stage 
B or C in 52 patients (33.5%). The proportion of surveillance failure 
to the Child-Pugh classification or institutional reference values 
(aspartate transaminase >34 IU/L, alanine transaminase >46 IU/
L, and creatinine ≥0.91 mg/dL). Factors with a P-value less than 
0.2 in the univariable analysis were included in the subsequent 
multivariable analysis. Odds ratios (ORs) and 95% confidence 
intervals (CIs) were calculated. The survival outcomes of the study 
subjects were analyzed according to whether surveillance failure 
occurred. Five-year overall survival (5YOS) was examined and 
compared using the Kaplan-Meier method with the log-rank test. 
For the survival analysis, patients were censored at the time of death 
or the last follow-up. All analyses were performed using statistical 
software (SPSS Statistics version 23.0, IBM Corp., Armonk, NY, USA), 
and a 2-sided P-value <0.05 was considered to indicate statistical 
significance.
Results
Patient Characteristics and Tumor Stage
The characteristics of the patients (113 men and 42 women) 
are summarized in Table 1. Hepatitis B virus infection was the 
predominant etiology of liver disease (81.9%), followed by hepatitis 
Table 1. Patient characteristics and tumor stages at initial diagnosis
No. of patients (%) US group (n=82) CT/MRI group (n=73) P-value Total (n=155)
Age (yr) 60.1±9.1 (39-84) 58.3±8.9 (35-77) 0.208 59.4±8.9 (35-84)
Male-to-female ratio 61:21 52:21 0.659 113:42
BMI (kg/m2) 22.7±2.6 23.2±2.9 0.222 22.9±2.7
≥25 kg/m2 15 (18.3) 19 (26.0) 0.245 34 (21.9)
Diabetes mellitus 29 (35.4) 37 (50.7) 0.054 66 (42.6)
Etiology of liver disease 0.590
Hepatitis B virus 69 (84.1) 58 (79.5) 127 (81.9)
Hepatitis C virus 7 (8.5) 10 (13.7) 17 (11.0)
Others 6 (7.3) 5 (6.8) 11 (7.1)
Child-Pugh classification 0.134
A 79 (96.3) 66 (90.4) 145 (93.5)
B 3 (3.7) 7 (9.6) 10 (6.5)
α-Fetoprotein ≥20 ng/mL 30 (36.6) 37 (50.7) 0.077 67 (43.2)
Quality of surveillance US
Inadequate echogenic window 12 (14.6) 14 (19.2) 0.450 26 (16.8)
Parenchymal macronodularity 52 (63.4) 58 (79.5) 0.028 110 (71.0)
Surveillance failure
Beyond the Milan criteria 19 (23.2) 12 (16.4) 0.296 31 (20.0)
BCLC stage B/C 29 (35.4)/4 (4.9) 16 (21.9)/3 (4.1) 0.061 45 (29.0)/7 (4.5)
Diagnosis at BCLC stage 0/at BCLC stage A, B, or C 17 (20.7)/65 (79.3) 23 (31.5)/50 (68.5) 0.126 40 (25.8)/115 (74.2)
Values are presented as mean±SD (range) or number (%).
US, ultrasonography; CT, computed tomography; MRI, magnetic resonance imaging; BMI, body mass index; BCLC, Barcelona Clinic Liver Cancer; SD, standard deviation.
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tended to be higher in the US group than in the CT/MRI group 
(23.2% vs. 16.4% by the Milan criteria [P=0.296] and 40.2% vs. 
26.0% by the BCLC staging system [P=0.061]). The proportion of 
diagnoses at BCLC stage 0 tended to be lower in the US group than 
in the CT/MRI group (20.7% vs. 31.5%, P=0.126).
US Quality and Tumor Stage in the US Group 
As summarized in Table 2, surveillance failure was more frequently 
observed in the US group in patients with an inadequate echogenic 
window (50.0% vs. 19.4% by the Milan criteria [P=0.046] and 
60.0% vs. 37.5% by the BCLC staging system [P=0.191]). The 
proportion of surveillance failure did not differ between patients 
with parenchymal macronodularity and those without parenchymal 
macronodularity (23.1% vs. 23.3% by the Milan criteria [P=0.979] 
and 38.5% vs. 43.3% by the BCLC staging system [P=0.665]). 
The frequency of diagnosis at BCLC stage 0 was not significantly 
Fig. 2. Inadequate echogenic window of surveillance ultrasonography (US) obscuring hepatocellular carcinoma in a 65-year-old man 
with B-viral liver cirrhosis. 
A, B. On US obtained through a subcostal view, segment IV of the liver is poorly visualized due to posterior shadowing from (A) hepatic 
flexure of the colon (arrowheads) and (B) the costochondral junction (arrow). C, D. Liver dynamic computed tomography was performed after 
3 months due to elevated serum α-fetoprotein levels and revealed a 6.3-cm mass in hepatic segment IV. The mass with hyperenhancement 
in the arterial phase (C) and washout in the portal venous phase (D) is located posterior to the hepatic flexure of the colon (arrowhead in C) 
and costochondral junction, which limited the echogenic window for this mass (arrow in C) on US. 
A B
C D
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Beyond the Milan criteria 5 (50.0) 14 (19.4) 0.046a) 12 (23.1) 7 (23.3) 0.979 19 (23.2)
BCLC stage B/C 6 (60.0)/0 23 (31.9)/4 (5.6) 0.191a) 17 (32.7)/3 (5.8) 12 (40.0)/1 (3.3) 0.665 29 (35.4)/4 (4.9)
Diagnosis at BCLC stage 0/at 
BCLC stage A, B, or C
1 (10.0)/9 (90.0) 16 (22.2)/56 (77.8) 0.679a) 10 (19.2)/42 (80.8) 7 (23.3)/23 (76.7) 0.659 17 (20.7)/65 (79.3)
Values are presented as number (%).
US, ultrasonography; BCLC, Barcelona Clinic Liver Cancer. 
a)P-values were obtained by the Fisher exact test.
Fig. 3. Parenchymal macronodularity 
hindering detection of hepatocellular 
carcinoma in a 45-year-old man with 
B-viral liver cirrhosis.
A. On the background of macronodular 
parenchyma, a 2.0-cm hypoechoic nodule 
(arrow) was undetected on surveillance 
ultrasonography (US). B. On the following 
US, performed after 6 months, the mass 
(arrow) increased in size but was still 
missed. C. On gadoxetate-enhanced 
l iver  dynamic magnet ic  resonance 
imaging (MRI) obtained after another 
6 months, the mass in hepatic segment 
V/VI measured 5.4 cm and showed 
hyperenhancement in the arterial phase 
and washout in the portal venous phase 
(not shown). D. T2-weighted MRI depicts 
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different according to adequacy of the echogenic window (10.0% 
vs. 22.2%, P=0.679) or parenchymal status (19.2% vs. 23.3%, 
P=0.659). 
Factors Related to Inadequate US Quality
The results of the univariable and multivariable regression analyses 
performed to examine the relationship of various clinical factors with 
an inadequate echogenic window and parenchymal macronodularity 
are presented in Table 3. In the multivariable analyses, BMI ≥25 
kg/m2 (OR, 2.536; 95% CI, 0.968 to 6.643; P=0.058) showed a 
tendency to be associated with an inadequate echogenic window; 
hepatitis B virus infection (OR, 10.370; 95% CI, 3.129 to 34.270; 
P<0.001) and a platelet count <150×109/L (OR, 3.167; 95% CI, 
1.360 to 7.375; P=0.008) were independently associated with 
parenchymal macronodularity.
Overall Survival
Patients with surveillance failure showed poorer survival outcomes 
than those without surveillance failure (5YOS, 36.4% vs. 69.9%; 
P<0.001 by the Milan criteria and 46.8% vs. 71.3%; P=0.001 by 
the BCLC staging system) (Fig. 4A, B).
Discussion
The results of our study indicate that the quality of surveillance US 
assessed by adequacy of the echogenic window and the presence 
of parenchymal macronodularity was associated with failure of 
surveillance for HCC. The majority of patients (79.5%) with HCC 
who were not diagnosed by US, but instead diagnosed by CT or MRI, 
had macronodular liver cirrhosis; this proportion was significantly 
higher than that in patients with HCC detected by surveillance US. 
HCC was detected by US beyond the Milan criteria in approximately 
one-fourth of study subjects; this was observed significantly more 
frequently in patients having an inadequate echogenic window, with 
surveillance failure occurring in 50% to 60% of such patients. We 
also found that diagnosis of HCC at later stages due to surveillance 
failure led to poorer survival outcomes.
Although US, the mainstay of HCC surveillance, has suboptimal 
sensitivity for the detection of early-stage HCC [9], few studies have 
evaluated the association between the adequacy of surveillance 
Table 3. Univariable and multivariable analyses of factors related to inadequate US quality
Variable
Inadequate echogenic window Parenchymal macronodularity













Age 1.039 0.990-1.090 0.117 1.036 0.986-1.088 0.163 0.973 0.936-1.012 0.173 - - -
Male 1.011 0.391-2.612 0.983 - - - 0.696 0.308-1.572 0.384 - - -
BMI ≥25 kg/m2 2.202 0.879-5.517 0.092 2.536 0.968-6.643 0.058 0.492 0.222-1.090 0.081 0.691 0.279-1.708 0.423
Diabetes mellitus 1.190 0.511-2.776 0.687 - - - 0.898 0.446-1.808 0.764 - - -
Etiology (reference: 
hepatitis C virus)
Hepatitis B virus 0.872 0.229-3.315 0.841 - - - 8.110 2.640-24.920 <0.001 10.370 3.129-34.270 <0.001
Non-B, non-C 1.750 0.283-10.810 0.547 - - - 4.200 0.838-21.047 0.081 5.216 0.908-29.955 0.064
Child-Pugh class 
(reference: A)
B 1.260 0.252-6.307 0.778 - - - 1.686 0.344-8.269 0.519 - - -
AST >34 IU/L 1.898 0.801-4.498 0.145 1.791 0.737-4.355 0.199 0.858 0.428-1.717 0.664 - - -
ALT >46 IU/L 0.786 0.273-2.262 0.655 - - - 2.327 0.892-6.068 0.084 2.275 0.812-6.377 0.118
Albumin <2.8 g/dL 2.540 0.222-29.097 0.454 - - - 0.815 0.072-9.218 0.869 - - -
Total bilirubin >3 mg/dL N/A N/A N/A - - - 0.815 0.072-9.218 0.869 - - -
Creatinine ≥0.91 mg/dL 1.263 0.543-2.937 0.587 - - - 0.918 0.458-1.841 0.810 - - -
Prothrombin time, INR 
>2.3
N/A N/A N/A - - - 0.197 0.017-2.232 0.190 0.516 0.039-6.817 0.615
Platelet count 
<150×109/L
2.383 0.770-7.376 0.132 2.689 0.825-8.765 0.101 2.619 1.243-5.515 0.011 3.167 1.360-7.375 0.008
AFP ≥20 ng/mL 0.789 0.333-1.871 0.591 - - - 1.059 0.525-2.136 0.872 - - -
US, ultrasound; CI, confidence interval; BMI, body mass index; AST, aspartate transaminase; ALT, alanine transaminase; INR, international normalized ratio; AFP, α-fetoprotein.
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US and surveillance failure. A previous study demonstrated that 
subcapsular location was more frequent among sonographically 
undetected nodules than among sonographically detected nodules 
[15]. The presence of an inadequate echogenic window, which was 
a variable assessed in our study, suggests that a non-negligible 
proportion of the liver is inappropriately visualized on US. Windows 
for subcapsular and dome locations would be particularly limited. 
Therefore, US may not be an appropriate modality for the detection 
of early-stage tumors when the echogenic window is not adequate. 
We also hypothesized that the detection of early-stage tumors may 
be challenging when numerous regenerative or dysplastic nodules 
are present in the liver. However, parenchymal macronodularity 
did not show a significant relationship with surveillance failure in 
the US group. This can be attributed to the fact that study subjects 
with parenchymal macronodularity frequently underwent CT or MRI 
due to clinical suspicion of liver cancer despite negative results on 
surveillance US. Interestingly, patients diagnosed by these alternative 
modalities showed a tendency to be diagnosed at early stages. Thus, 
we can speculate that parenchymal macronodularity may hinder the 
detection of small tumors and that using an imaging modality other 
than US may help prevent surveillance failure. A previous study 
demonstrated that parenchymal macronodularity was a significant 
factor related to surveillance failure, especially in patients with 
hepatitis B virus infection [13]. Those results seem to be applicable 
to our study population, probably due to the high prevalence of 
hepatitis B virus infection in our study.
We found that a high BMI was marginally associated with an 
inadequate echogenic window, even though only a small proportion 
of our study subjects was classified as overweight based on 
BMI values. Although a previous analysis revealed no significant 
association between BMI and surveillance failure [10], another 
study that recruited a larger number of obese or morbidly obese 
patients demonstrated a significant association between high BMI 
and surveillance failure [11]. Our results indicate that a large patient 
body habitus can negatively affect the quality of the echogenic 
window and thereby interfere with tumor detection by US. However, 
BMI was not an independent contributor to a poor echogenic 
window. This may be explained by the fact that thin patients 
occasionally have an inadequate echogenic window depending on 
the configuration of the rib cage and intra-abdominal organs; liver 
parenchymal atrophy due to advanced liver cirrhosis can also make 
the echogenic window inadequate. Therefore, routine assessment of 
echogenic window quality in each patient during surveillance would 
be practically useful and provide critical information for planning the 
next surveillance modality.
It should be noted that patients with hepatitis B infection were 
more likely to exhibit parenchymal macronodularity than were 
patients with hepatitis C infection, with an OR of 10.370. This 
Fig. 4. Kaplan-Meier survival curves according to whether surveillance failure occurred.
Survival outcomes were poorer in patients with surveillance failure (A, 5-year overall survival, 36.4% vs. 69.9%; P<0.001 by the Milan 
criteria; B, 46.8% vs. 71.3%; P=0.001 by the Barcelona Clinic Liver Cancer [BCLC] staging system).
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result, in accordance with prior knowledge [16], is significant in 
that the quality of surveillance US may depend on the etiology 
of liver disease. In patients with hepatitis B virus infection, US 
surveillance may show a limited ability to detect early-stage HCC. 
A low platelet count also showed a significant association with 
parenchymal macronodularity. A low platelet count, representing 
portal hypertension [17], may reflect the advanced status of the 
underlying liver disease itself, as is demonstrated by a macronodular 
appearance of the liver parenchyma on US.
The results of our study suggest that US surveillance has 
limitations in patients with an inadequate echogenic window or 
parenchymal macronodularity. Moreover, BCLC stage 0 tumors 
accounted for approximately 20% of the total tumors in the 
US group, regardless of the quality of the echogenic window or 
parenchymal status. This indicates that diagnosing tumors at a very 
early stage is challenging when US is used for surveillance, even 
with adequate US quality. Therefore, an alternative surveillance 
method, such as MRI, may be helpful to prevent surveillance failure 
and to facilitate tumor diagnosis at the earliest stage. Compared 
to US, MRI with a hepatobiliary contrast agent has shown superior 
detection sensitivity for early-stage HCC and a lower false-positive 
rate [15]. Further investigations are warranted to validate the utility 
of imaging modalities other than US, including unenhanced MRI, in 
patients prone to surveillance failure [18,19]. 
This study has some limitations. First, this is a single-center 
study that included noncirrhotic hepatitis C patients, which may 
limit the generalizability of our results. Second, as US examinations 
were performed by multiple operators, inter-observer variability in 
reporting echogenic window quality existed. However, we could 
not perform a retrospective analysis of this variable, as the degree 
to which echogenic window quality can be determined based on 
images alone is limited. Third, we only examined the adequacy of US 
examinations in terms of the echogenic window and parenchymal 
status. Other factors, including the degree of fatty liver, tumor size, 
tumor location, as well as elastography measurements of liver 
stiffness, may also be related to tumor detectability on US. Lastly, the 
major etiology of liver disease was hepatitis B virus infection in our 
study population, which limits the applicability of our results to the 
general high-risk population. However, our study demonstrated that 
parenchymal macronodularity significantly influenced the detection 
sensitivity of surveillance US in an area with endemic hepatitis B 
virus infections.
In conclusion, an inadequate echogenic window and parenchymal 
macronodularity may be associated with a higher risk of surveillance 
failure. Alternative surveillance strategies may be helpful for early 
tumor detection in patients with inadequate US quality.
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